TIDMOXB
RNS Number : 4501P
Oxford Biomedica PLC
19 October 2021
Oxford Biomedica Announces that Boehringer Ingelheim has
Exercised Option Relating to a Novel Gene Therapy Treatment for
Cystic Fibrosis
Oxford, UK - 19 October 2021: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, today announces that Boehringer Ingelheim has
exercised its option to license Oxford Biomedica's lentiviral
vector technology to manufacture, register and commercialise BI
3720931, a lentiviral vector-based gene therapy for the treatment
of cystic fibrosis (CF).
Under the terms of the option and license agreement with
Boehringer Ingelheim, originally announced in August 2018,
Boehringer Ingelheim will pay Oxford Biomedica an option exercise
fee of GBP3.5 million. Oxford Biomedica is further entitled to
development, regulatory and sales milestones of up to a further
GBP27.5 million, in addition to a tiered low single digit royalty
on net sales of a CF gene therapy product. This option exercise by
Boehringer Ingelheim follows on another recent signature of a
Development & Supply Agreement which was announced in April
2021, relating to the clinical manufacture of various types of
viral vector based products.
In parallel, Boehringer Ingelheim has also exercised its option
to license intellectual property and know-how from IP Group and the
UK Cystic Fibrosis Gene Therapy Consortium relating to the same
lentiviral vector-based product candidate for the treatment of
CF.
This innovative development partnership between academia, Pharma
and Biotech focuses on the development of a novel, replication
deficient lentiviral vector, in an inhaled formulation, to
selectively introduce a CFTR gene into the relevant target cell.
This approach has demonstrated high gene transfer efficiency and
offers the possibility of repeated administration to maintain a
therapeutic effect. In addition, the approach has the potential to
address all of the more than 2,000 different known gene mutations
across CF patients, and therefore offers a gene-independent
disease-modifying treatment option for patients.
Should the program progress into clinical development, Oxford
Biomedica expects to produce large quantities of lentiviral vectors
using its highly efficient GMP-compliant manufacturing process in
bioreactors.
To read the full Boehringer Ingelheim press release please
follow this link:
http://www.boehringer-ingelheim.com/press-release/cystic-fibrosis-genetherapy-development-option-excercise
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
"We have enjoyed working with Boehringer Ingelheim, IP Group, and
the UK Cystic Fibrosis Gene Therapy Consortium since 2018. Building
on the great progress made to date, we are delighted that
Boehringer Ingelheim, one of the world's leading respiratory
medicine organisations, has chosen to exercise the option to
license Oxford Biomedica's lentiviral vector manufacturing
technology for this highly innovative inhaled cystic fibrosis gene
therapy formulation developed by the UK Cystic Fibrosis Gene
Therapy Consortium. This partnership is central to our company's
mission of delivering life changing gene therapies to patients and
has the potential to provide a new therapeutic option for many
cystic fibrosis patients globally."
Clive R. Wood, Ph.D., Corporate Senior Vice President and Global
Head of Discovery Research at Boehringer Ingelheim, said: "Since
2018, Boehringer Ingelheim has sponsored research and development
activities with the UK Cystic Fibrosis Gene Therapy Consortium and
Oxford Biomedica. The shared success achieved with our partners in
this potentially revolutionary project makes us confident that we
can now further accelerate this highly innovative therapeutic
approach. With our leadership in the discovery and development of
therapies in respiratory diseases combined with the gene therapy
and manufacturing knowledge of our partners, we aim to bring the
next breakthrough to patients suffering from CF, who are
desperately waiting for better options."
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, CNS disorders and liver diseases. The Group has also
entered into a number of partnerships, including with Novartis,
Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics,
Santen, Beam Therapeutics and Boehringer Ingelheim, through which
it has long-term economic interests in other potential gene and
cell therapy products. Additionally, the Group has signed a 3-year
master supply and development agreement with AstraZeneca for
large-scale manufacturing of the adenoviral based COVID-19 vaccine
candidate, AZD1222. Oxford Biomedica is based across several
locations in Oxfordshire, UK and employs more than 740 people.
Further information is available at www.oxb.com
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that
improve the lives of humans and animals. As a leading
research-driven biopharmaceutical company, the company creates
value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim
takes a long-term perspective. Around 52,000 employees serve more
than 130 markets in the three business areas, Human Pharma, Animal
Health, and Biopharmaceutical Contract Manufacturing. Learn more at
www.boehringer-ingelheim.com
About Cystic Fibrosis
Cystic Fibrosis is a rare, progressive, life-threatening disease
that results in severe dysfunction and persistent infections of the
lung affecting 70,000 people worldwide. It is caused by a defective
or absent protein that results from mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene. This
innovative development partnership among academia, life science
investors, pharma, and biotech focusses on the advancement of BI
3720931, a novel, replication deficient lentiviral vector, in an
inhaled formulation, which selectively introduces a healthy CFTR
gene into the relevant target cells.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZMMGGRMGMZZ
(END) Dow Jones Newswires
October 19, 2021 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2023 to Mar 2024